Scorr-Insert
X

Find Novel Oncology Drugs in Preclinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NRP2 Antibodies

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 20, 2020

            Details:

            Poster details data from aTyr’s pre-clinical, domain specific Neuropilin-2 (NRP2) antibody program highlighting therapeutic potential in triple-negative breast cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): FT538

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 20, 2020

            Details:

            The Company plans to initiate clinical investigation of three once-weekly doses of FT538 as a monotherapy in acute myeloid leukemia (AML) and in combination with daratumumab, a CD38-directed monoclonal antibody therapy, for the treatment of multiple myeloma.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Salinomycin

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 19, 2020

            Details:

            Abstracts highlight data from HSB-1216 (Salinomycin QUATRAMER™) in small cell lung cancer and triple negative breast cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tucatinib

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 18, 2020

            Details:

            Highlights from 12 presentations showcasing its research and development portfolio of novel targeted therapies and antibody-drug conjugate technology advances and innovation will be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting II.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Alphale-Exatecan

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 15, 2020

            Details:

            CBX-12 demonstrated remarkable efficacy across HER2-negative solid tumors in preclinical models. It displayed enhanced stability in plasma in vivo and demonstrated exquisite selectivity for tumor over normal tissues in mouse tumor models.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): exoVACC

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 15, 2020

            Details:

            exoVACC™ modular vaccine platform induces potent systemic and tissue resident T cell response.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 15, 2020

            Details:

            Data to be presented at 2020 AACR Annual Meeting show HPK1 inhibition produced robust anti-tumor response in mouse model.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ATA2271

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 15, 2020

            Details:

            First published data with novel 1XX CAR signaling and programmed death-1 (PD-1) dominant negative receptor (DNR) checkpoint inhibition technologies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IMGN151

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 15, 2020

            Details:

            In preclinical models, IMGN151 showed activity not only in high FRα-expressing tumors, but also improved activity in medium and low FRα-expressing tumors, suggesting promising potential in a broad set of patients with an array of tumor types.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NL-201

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 15, 2020

            Details:

            The presentations include preclinical data on lead candidate NL-201, as well as other applications of Neoleukin’s de novo protein design platform.

            PharmaCompass